Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence

被引：28
作者：
DePriest A.Z. [1 ,2 ]
Miller K. [1 ,2 ]
机构：
[1] Aegis Sciences Corporation, Nashville, TN
[2] University of Tennessee College of Pharmacy, Memphis, TN
来源：
Pain and Therapy | 2014年 / 3卷 / 1期
关键词：
Abuse-deterrent formulations; Chronic pain treatment; Opioid-induced constipation; Opioids; Oxycodone/naloxone;
D O I：
10.1007/s40122-014-0026-2
中图分类号：
学科分类号：
摘要：
The use of opioids in the treatment of chronic pain is widespread; the prevalence of specific opioids varies from country to country and depends on product availability, national formulary systems, and provider preferences. Patients often receive opioids for legitimate treatment of pain conditions, but on the opposite side of the spectrum, nonmedical use of opioids is a significant public health concern. Opioids are associated with several side effects, and constipation is the most commonly reported and persistent symptom. Unlike some adverse effects associated with opioid use, tolerance does not develop to constipation. Opioid-induced constipation (OIC) is the most prevalent patient complaint associated with opioid use and has been associated with declines in various quality of life measures. OIC can be extremely difficult for patients to tolerate and may prompt patients to decrease or discontinue opioid treatment. Current management strategies for OIC are often insufficient. A prolonged-release formulation of oxycodone/naloxone (OXN) has been investigated for the treatment of nonmalignant and cancer pain and mitigation of OIC, and evidence is largely favorable. Studies have demonstrated the capability of OXN to alleviate OIC while maintaining pain control comparable to oxycodone-only regimens. There is insufficient evidence for OXN efficacy for patients with mild OIC or patients maintained on high doses of opioids, and use in these populations is controversial. The reduction of costs associated with OIC may provide overall cost effectiveness with OXN. Additionally, the presence of naloxone may deter abuse/misuse by those seeking to misuse the formulation by modes of administration other than oral ingestion. Most studies to date have occurred in European countries, and phase 3 trials continue in the United States. This review will include current therapeutic options for pain and constipation, unique characteristics of OXN, evidence related to use of OXN and its place in therapy, discussion of opioid abuse/misuse, and various abuse-deterrent mechanisms, and areas of continuing research. © 2014, The Author(s).
引用
收藏
页码：1 / 15
页数：14
相关论文
共 101 条
[51]  
Muller-Lissner S., Leyendecker P., Hopp M., Ruckes C., Fleischer W., Reimer K., Oral prolonged release (PR) oxycodone/naloxone combination reduces opioid-induced bowel dysfunction (OIBD) in patients with severe chronic pain, Eur J Pain, 11, (2007)
[52]  
Vondrackova D., Leyendecker P., Meissner W., Et al., Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain, J Pain, 9, 12, pp. 1144-1154, (2008)
[53]  
Simpson K., Leyendecker P., Hopp M., Et al., Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain, Curr Med Res Opin, 24, 12, pp. 3503-3512, (2008)
[54]  
Lowenstein O., Leyendecker P., Hopp M., Et al., Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial, Expert Opin Pharmacother, 10, 4, pp. 531-543, (2009)
[55]  
Nadstawek J., Leyendecker P., Hopp M., Et al., Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain, Int J Clin Pract, 62, 8, pp. 1159-1167, (2008)
[56]  
Ahmedzai S.H., Nauck F., Bar-Sela G., Bosse B., Leyendecker P., Hopp M., A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain, Palliat Med, 26, 1, pp. 50-60, (2012)
[57]  
Ueberall M.A., Muller-Lissner S., Buschmann-Kramm C., Bosse B., The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients, J Int Med Res, 39, 1, pp. 41-50, (2011)
[58]  
Rentz A.M., Yu R., Muller-Lissner S., Leyendecker P., Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation, J Med Econ, 12, 4, pp. 371-383, (2009)
[59]  
Foundation R., Guidelines—Rome III diagnostic criteria for functional gastrointestinal disorders, J Gastrointest Liver Dis, 15, 3, pp. 307-312, (2006)
[60]  
Sandner-Kiesling A., Leyendecker P., Hopp M., Et al., Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain, Int J Clin Pract, 64, 6, pp. 763-774, (2010)
12345678910